All participants achieved weight loss of at least 5%, 93% achieved weight loss of at least 10% and 83% achieved weight loss of at least 15%
GLP-1 agonists benefit MASH patients by reducing liver fat, decreasing inflammation, and hence improving liver tissue structure, potentially slowing the progression of the disease
Retatrutide is obtained through a licensed healthcare provider who evaluates your health history, goals, and eligibility
The dosage for each drug across all groups was standardized at 5 mg/kg to ensure consistency in the assessment

Before starting any new supplement, it is advisable to: Consult your GP or a registered pharmacist , particularly if you have an existing medical condition, are pregnant or breastfeeding, or are taking prescribed medications Check the product label carefully for dosage instructions, ingredient lists, and any allergen information Choose products from reputable manufacturers that comply with UK food supplement regulations enforced by the FSA Avoid exceeding the manufacturer's recommended dose , as higher doses have not been shown to confer additional benefit and may increase the risk of adverse effects Additional cautions apply to specific groups: People with kidney (renal) disease should seek medical advice before taking L-carnitine supplements, as unsupervised use is not recommended in this group Children and adolescents should not take L-carnitine supplements unless specifically advised to do so by a clinician People taking anticoagulants such as warfarin should speak to their GP or anticoagulation service before use
